<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Acta Naturae</journal-id><journal-title-group><journal-title xml:lang="en">Acta Naturae</journal-title><trans-title-group xml:lang="ru"><trans-title>Acta Naturae</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-8251</issn><publisher><publisher-name xml:lang="en">Acta Naturae Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10847</article-id><article-id pub-id-type="doi">10.32607/20758251-2019-11-2-63-67</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Research Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Экспериментальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The Role of Recombinant Human Cyclophilin A in the Antitumor Immune Response</article-title><trans-title-group xml:lang="ru"><trans-title>Роль рекомбинантного циклофилина А человека в развитии противоопухолевого иммунного ответа</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kalinina</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Калинина</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>lkhromykh@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Silaeva</surname><given-names>Yu. Yu.</given-names></name><name xml:lang="ru"><surname>Силаева</surname><given-names>Ю. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>lkhromykh@list.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kazansky</surname><given-names>D. B.</given-names></name><name xml:lang="ru"><surname>Казанский</surname><given-names>Д. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>lkhromykh@list.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khromykh</surname><given-names>L. M.</given-names></name><name xml:lang="ru"><surname>Хромых</surname><given-names>Л. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>lkhromykh@list.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of Gene Biology Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт биологии гена РАН</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Министерства здравоохранения России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2019</year></pub-date><volume>11</volume><issue>2</issue><issue-title xml:lang="en">VOL 11, NO2 (2019)</issue-title><issue-title xml:lang="ru">ТОМ 11, №2 (2019)</issue-title><fpage>63</fpage><lpage>67</lpage><history><date date-type="received" iso-8601-date="2020-01-21"><day>21</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Kalinina A.A., Silaeva Y.Y., Kazansky D.B., Khromykh L.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Калинина А.А., Силаева Ю.Ю., Казанский Д.Б., Хромых Л.М.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Kalinina A.A., Silaeva Y.Y., Kazansky D.B., Khromykh L.M.</copyright-holder><copyright-holder xml:lang="ru">Калинина А.А., Силаева Ю.Ю., Казанский Д.Б., Хромых Л.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://actanaturae.ru/2075-8251/article/view/10847">https://actanaturae.ru/2075-8251/article/view/10847</self-uri><abstract xml:lang="en"><p>Cyclophilin A (CypA) is a multifunctional protein that exhibits an isomerase activity and exists in the intracellular and secretory forms. Secretory CypA promotes regeneration of the hematopoietic and the immune systems of an organism by stimulating stem cell migration from the bone marrow. New approaches based on CypA are currently being developed for the treatment of limb ischemia, neutralization of the side effects of Cyclosporine A (CsA) therapy, etc. However, the role of CypA in the antitumor immune response is still unexplored. In this work, we used the model experimental system of lymphoma EL-4 rejection in B10.D2(R101) mice and showed that recombinant human CypA (rhCypA) stimulates the antitumor immune response via early recruitment of granulocytes to the tumor cell localization site and rapid accumulation of effector T-killers</p></abstract><trans-abstract xml:lang="ru"><p>Циклофилин А (ЦфА) - многофункциональный белок, обладающий изомеразной активностью и существующий во внутриклеточной и секретируемой формах. Секретируемый ЦфА способствует ре генерации кроветворной и иммунной систем организма, усиливая миграцию стволовых клеток из костного мозга. В настоящее время разрабатываются стратегии применения ЦфА при ишемии конечностей, для устранения побочных эффектов циклоспорина А (ЦсА) и др. Однако роль ЦфА в развитии противоопухолевого иммунного ответа не изучена. Используя модельную систему отторжения лимфомы EL-4 мышами B10.D2(R101), нами показано, что рекомбинантный ЦфА человека стимулирует противоопухолевый иммунный ответ за счет раннего привлечения гранулоцитов в сайт локализации клеток-мишеней и ускоренного системного накопления эффекторных Т-киллерных клеток.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Cyclophilin A</kwd><kwd>pro-inflammatory factor</kwd><kwd>antitumor immune response</kwd><kwd>transgenic mice</kwd><kwd>T-cell receptor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>провоспалительный фактор</kwd><kwd>противоопухолевый иммунный ответ</kwd><kwd>трансгенные мыши</kwd><kwd>Т-клеточный рецептор</kwd><kwd>циклофилин А</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>[1] Nigro P., Pompilio G., Capogrossi M.C. // Cell Death Disease. 2013, V.4, 10.1038/cddis.2013.410., P. e888</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>[2] Khromykh L.M., Kulikova N.L., Anfalova T.V., Muranova T.A., Abramov V.M., Vasiliev A.M., Khlebnikov V.S., Kazansky D.B. // Cell Immunol. 2007, V.249, №1, P.46-53</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>[3] Dawar F.U., Xiong Y., Khattak M.N.K., Li J., Lin L., Mei J. // J. Leukoc. Biol. 2017, V.102, №4, P.989-992</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>[4] Bharadwaj U., Zhang R., Yang H., Doan D., Li M., Chen C., Yao Q. // J. Surgical Res. 2004, V.121, №2, P.294</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>[5] Silaeva Yu.Yu., Kalinina A.A., Vagida M.S., Khromykh L.M., Deikin A.V., Ermolkevich T.G., Sadchikova E.R., Goldman I.L., Kazansky D.B. // Biochemisty. 2013, V.78, №5, P.614-626</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>[6] Khromykh L.M., Kalinina A.A., Kozyr A.V., Kolesnikov A.V., Silaeva Yu.Yu., Kazansky D.B. // Patent № 2603283. Russian Federation. 2015</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>[7] Silaeva Yu.Yu., Grinenko T.S., Vagida M.S., Kalinina A.A., Khromykh L.M., Kazansky D.B. // J. Immunotoxicol. 2014, V.1, №4, P.393-399</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>[8] Mantovani A., Cassatella M.A., Costantini C., Jaillon S. // Nat Rev Immunol. 2011, V.11, №8, P.519-523</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>[9] Takashima A., Yao Y. // J Leukoc Biol. 2015, V.98, №4, P.489-496</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>[10] Maryukhnich E.V., Zvezdova E.S., Anfalova T.V., Khromykh L.M., Kazansky D.B. // Docl. Biol. Sci. 2007, V.414, №1, P.242-245</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>[11] Pobezinskii L.A., Pobezinskaya E.L., Zvezdova E.S., Petrishchev V.N., Grinenko T.S., Baturina I.A., Anfalova T.V., Khromykh L.M., Vasil’eva T.V., Kazanskii D.B. // Dokl Biol Sci. 2005, V.402, №3, P.224-229</mixed-citation></ref></ref-list></back></article>
